Research sheds light on what causes severe inflammatory bowel disease.

Published Date: 26 Apr 2023

Researchers from Cedars-Sinai have discovered a genetic variation that raises the risk of perianal Crohn's disease, the most crippling form of the condition, in susceptible individuals.

Read Full News

Latest News

Unraveling the Complexities of Concomitant IBD and Hepatobiliary Disease, With Natalia Nedelkopoulou, MD Natalia Nedelkopoulou, MD

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Navigating Autoimmune Overlap in Celiac Disease, With Daniel Mallon, MD Daniel Mallon, MD

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD Bruce Sands, MD

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Todays Updates

Rural Accountable Care Organizations: Better Diabetes Care

Participation in accountable care organizations shows better diabetes care outcomes for patients in rural areas than for those in urban settings.

Sex Disparity Seen in Response to Growth Therapy in 21-OHD

In patients with classical 21-hydroxylase deficiency, growth-promoting therapies have variable effects: They increase final height relative to midparental height in boys but not in girls.

Higher Relative Fat Mass Is Linked With Chronic Diarrhea

Higher relative fat mass is associated with increased odds of having chronic diarrhea, although the measure alone shows limited ability to predict risk.

Diabetes in Mothers Tied to Epilepsy Risk in Offspring

Risk rises with all three types of diabetes mellitus but mostly with type 2.

Managing Constipation in Patients on GLP-1s

As GLP-1 use rise, constipation remains a leading cause of discontinuation. Experts offer practical strategies for prevention and management.

Dapagliflozin Can Reduce Liver Fat in Diabetes

In patients with type 2 diabetes, 12 months of dapagliflozin therapy is significantly associated with reduced liver fat, independent of weight loss or other metabolic benefits.

Diabetes Remission Is Possible, but There’s Not Just One Way

Physicians must deploy specific tools in specific ways at specific times — adding to the time-consuming treatment costs.

Todays Updates

Rural Accountable Care Organizations: Better Diabetes Care

Participation in accountable care organizations shows better diabetes care outcomes for patients in rural areas than for those in urban settings.

Sex Disparity Seen in Response to Growth Therapy in 21-OHD

In patients with classical 21-hydroxylase deficiency, growth-promoting therapies have variable effects: They increase final height relative to midparental height in boys but not in girls.

Higher Relative Fat Mass Is Linked With Chronic Diarrhea

Higher relative fat mass is associated with increased odds of having chronic diarrhea, although the measure alone shows limited ability to predict risk.

Diabetes in Mothers Tied to Epilepsy Risk in Offspring

Risk rises with all three types of diabetes mellitus but mostly with type 2.

Managing Constipation in Patients on GLP-1s

As GLP-1 use rise, constipation remains a leading cause of discontinuation. Experts offer practical strategies for prevention and management.

Dapagliflozin Can Reduce Liver Fat in Diabetes

In patients with type 2 diabetes, 12 months of dapagliflozin therapy is significantly associated with reduced liver fat, independent of weight loss or other metabolic benefits.

Diabetes Remission Is Possible, but There’s Not Just One Way

Physicians must deploy specific tools in specific ways at specific times — adding to the time-consuming treatment costs.

Latest News

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

News All Time

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Gastroenterology in 2025: Year in Review

Gastroenterology in 2025: Year in Review

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD Thomas Wallach, MD

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

5 Gastroenterology Headlines You Missed in November 2025

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Recommended News For You

The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.

Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.

Dr. Prerana S. Nesargi's message for Childhood Cancer Awareness Month 2023 is to increase understanding of pediatric oncology.

Housing aid linked to lower medical financial hardship among US renters with cancer

Loneliness and social isolation linked to heightened risk of death in those with cancer

Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

Recommended Articles For You

Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer 

Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor 

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Housing aid linked to lower medical financial hardship among US renters with cancer

2.

Review looks at potential treatment targets in the tumor microenvironment.

3.

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

4.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

5.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

1.

Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options 

2.

All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment

3.

Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment

4.

Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options 

5.

Clinical Analysis of Prostate Cancer

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

3.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

5.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot